% | $
Quotes you view appear here for quick access.

Incyte Corporation Message Board

  • pharmachemist1 pharmachemist1 Nov 11, 2012 5:51 PM Flag

    November 11, 2012. Lilly poster #490 on ACR Annual Meeting. Baricitinib - Positive news for Incyte.

    Today LLY presented poster #490 on phase 2b dose-ranging study of Baricitinib in RA.
    Full abstract is availabe on ACR web page.
    Below you can read poster summary.

    Background/Purpose: Baricitinib (formerly, LY3009104/INCB028050) is a novel, oral inhibitor of the JAK1 and JAK2 in the JAK-STAT pathway known to be of importance in the pathobiology of rheumatoid arthritis (RA) and has previously been shown to improve the signs and symptoms of RA after 12 weeks of treatment.1 This study evaluates the patient-reported outcomes (PROs) within a 24-week blinded phase 2b study for 1 mg, 2 mg, 4 mg, and 8 mg baricitinib once daily (QD) at 12 weeks, and 4 mg and 8 mg at 24 weeks.

    Results: Of 301 randomized patients, those who received baricitinib experienced clinically meaningful improvements in most PROs as early as week 2 vs. PBO as well as at 12 weeks (Table 1). These improvements were maintained or continued to improve through 24 weeks (e.g., change from baseline for 4 and 8 mg groups, respectively, FACIT-F: 5.32 [SEM: 1.31], 5.00 [SEM: 1.52]; SF-36 PCS: 7.32 [SEM: 0.97], 7.67 [SEM: 1.23]).

    Conclusion: : In this phase 2b study in patients with RA, those who received baricitinib reported clinically meaningful improvements as early as week 2 in most PROs relative to PBO as well as at 12 weeks. These improvements were maintained or continued to improve through 24 weeks.


    Good news for INCY!. Great chance to develop SMALL and ORAL molecule for RA.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
86.41-1.38(-1.57%)Jul 22 4:00 PMEDT